Today: 7 February 2026
Subscribe
Browse Category

NYSE:JNJ News 17 November 2025 - 15 December 2025

Johnson & Johnson Stock (JNJ) Today: FDA Fast‑Track Voucher Lifts Oncology Narrative as Talc Verdict Renews Legal Overhang

Johnson & Johnson Stock (JNJ) Today: FDA Fast‑Track Voucher Lifts Oncology Narrative as Talc Verdict Renews Legal Overhang

Johnson & Johnson stock (NYSE: JNJ) is starting the week at the center of two storylines that often tug the share price in opposite directions: accelerating momentum in oncology and a stubborn, headline‑driven litigation risk. On Monday, December 15, 2025, JNJ shares traded around the $214 level, brushing the upper end of their recent trading range and extending a rally that has put the healthcare bellwether sharply higher on the year. Investing.com+2MarketScreener+2 What’s moving JNJ today isn’t a single earnings surprise. Instead, it’s a high‑impact regulatory catalyst—a newly granted FDA priority voucher tied to a multiple myeloma regimen—arriving the same
15 December 2025
··
Healthcare & Pharma Giants US Stocks: Week Ahead Outlook After Eli Lilly’s Retatrutide, CVS Guidance, Pfizer’s Obesity Deal, and J&J’s Talc Verdict (Updated Dec. 14, 2025)

Healthcare & Pharma Giants US Stocks: Week Ahead Outlook After Eli Lilly’s Retatrutide, CVS Guidance, Pfizer’s Obesity Deal, and J&J’s Talc Verdict (Updated Dec. 14, 2025)

Updated: December 14, 2025Coverage window for this report: December 8–14, 2025 Wall Street heads into the week of Dec. 15, 2025 with U.S. healthcare and pharma mega-caps back in the spotlight—pulled by three powerful forces that all intensified in the last seven days: (1) the obesity-drug arms race, (2) Washington’s policy crosscurrents around insurance subsidies and PBM transparency, and (3) a faster-moving FDA that is simultaneously accelerating reviews and reopening safety scrutiny in sensitive pediatric categories. Reuters+3Reuters+3Reuters+3 The result is a “defensive sector” that doesn’t feel defensive at all right now. The Federal Reserve’s Dec. 9–10 meeting delivered another layer
14 December 2025
······
Johnson & Johnson Stock (JNJ) Jumps Near 52-Week Highs on FDA Approval and Oncology Data — Week in Review, Week Ahead (Updated Dec. 12, 2025)

Johnson & Johnson Stock (JNJ) Jumps Near 52-Week Highs on FDA Approval and Oncology Data — Week in Review, Week Ahead (Updated Dec. 12, 2025)

(SEO): Johnson & Johnson (NYSE: JNJ) climbed to $211.58 this week as investors weighed FDA approval news, breakthrough oncology data, and fresh talc-trial risk. Reuters+3Investing.com+3JNJ.com+3 Johnson & Johnson stock (NYSE: JNJ) capped a volatile but decisively positive week by closing at $211.58 on Friday, Dec. 12, 2025, extending a sharp rebound that pushed shares to the doorstep of fresh 52‑week highs. Investing.com The move came as investors digested a cluster of market-moving headlines: At the macro level, the Federal Reserve’s quarter-point rate cut earlier in the week added another tailwind for large, defensive healthcare names as investors rotated toward perceived
13 December 2025
··
Johnson & Johnson (JNJ) Stock News Today, Forecasts and Analyst Targets (Dec. 12, 2025)

Johnson & Johnson (JNJ) Stock News Today, Forecasts and Analyst Targets (Dec. 12, 2025)

Published: December 12, 2025 Johnson & Johnson stock (NYSE: JNJ) is ending the week in the spotlight as shares hover near record territory, helped by a steady stream of analyst target updates, fresh late-stage clinical data disclosures, and a clearer roadmap for portfolio reshaping heading into 2026. As of 14:33 UTC on Dec. 12, 2025, JNJ shares traded at $210.50, up 0.23% on the day, after opening near $210.89 and trading between $208.50 and $210.89. JNJ stock price today: near a record after Thursday’s all-time high close JNJ is coming off a notable milestone: Yahoo Finance historical data shows JNJ
12 December 2025
·
Johnson & Johnson (JNJ) Stock Hits New High After the Bell on December 11, 2025 – What to Know Before the December 12 Open

Johnson & Johnson (JNJ) Stock Hits New High After the Bell on December 11, 2025 – What to Know Before the December 12 Open

Johnson & Johnson (NYSE: JNJ) closed regular trading on Thursday, December 11, 2025 at $210.01, up about 1.7% on the day, marking a fresh 52‑week high before easing slightly in after‑hours trading around $209.25. MarketScreener+1 That move capped a week of bullish Wall Street calls, powerful oncology data out of the ASH 2025 hematology meeting, and renewed focus on the company’s dealmaking and ongoing legal overhangs. Here’s what happened after the bell on December 11 – and what traders and longer‑term investors should watch heading into the December 12, 2025 U.S. market open. How JNJ Traded on December 11, 2025
12 December 2025
·
Johnson & Johnson (JNJ) Stock Near Record Highs: Latest News, Legal Risks and 2026 Outlook for Investors

Johnson & Johnson (JNJ) Stock Near Record Highs: Latest News, Legal Risks and 2026 Outlook for Investors

Johnson & Johnson stock has gone from sleepy blue chip to market star in 2025. As of the morning of December 11, 2025, JNJ trades around $208 per share, sits at an estimated $500+ billion market capitalization, and is at its 52‑week high after a powerful rally that has outpaced the S&P 500. StockAnalysis+1 Since November 21, 2025, the story around Johnson & Johnson has been driven by three big themes: Below is a detailed, news‑driven look at Johnson & Johnson stock, recent catalysts, risks and the current Wall Street forecast as of December 11, 2025. JNJ stock today: price,
11 December 2025
·
Johnson & Johnson (JNJ) Stock After the Bell on December 10, 2025 – And What to Watch Before the December 11 Open

Johnson & Johnson (JNJ) Stock After the Bell on December 10, 2025 – And What to Watch Before the December 11 Open

Johnson & Johnson stock is back in the market’s spotlight. After a powerful run in 2025, JNJ is now trading just under record highs as investors juggle two very different narratives: blockbuster oncology and immunology growth on one side, and grinding talc litigation plus regulatory noise on the other. On Wednesday, December 10, 2025, JNJ closed at $206.54, up 3.3% on the day, after trading between $200.18 and $206.80 with heavy volume of roughly 11.4 million shares. That puts the stock less than 1% below its 52‑week high of $207.81. Investing.com+1 After the bell, after‑hours trading nudged JNJ modestly higher,
11 December 2025
··
Johnson & Johnson (JNJ) Stock on December 10, 2025: Pipeline Breakthroughs, Talc Risks and What Analysts Expect Next

Johnson & Johnson (JNJ) Stock on December 10, 2025: Pipeline Breakthroughs, Talc Risks and What Analysts Expect Next

Updated: December 10, 2025 Johnson & Johnson (NYSE: JNJ) is trading near fresh highs as investors weigh powerful growth drivers in oncology and immunology against a still‑messy overhang from talc litigation. As of late trading on December 10, 2025, JNJ changes hands around $203–204 per share, up roughly 1.9% on the day, with an intraday high just above $204 and a low near $200. The stock has rallied roughly 38–41% year to date, handily beating many healthcare peers and broader indexes. Nasdaq+1 Today’s move comes as investors digest fresh Phase 3 cancer data, continued buying (and some selling) by institutional
10 December 2025
···
Johnson & Johnson (JNJ) Stock After Hours on December 9, 2025: New Cancer Breakthrough, Dividend Payout and What to Watch Before the December 10 Open

Johnson & Johnson (JNJ) Stock After Hours on December 9, 2025: New Cancer Breakthrough, Dividend Payout and What to Watch Before the December 10 Open

Key Takeaways Below, we’ll walk through what happened to Johnson & Johnson stock after the bell on December 9 and what investors should watch before the U.S. market opens on Wednesday, December 10, 2025. 1. How Johnson & Johnson Stock Traded on December 9, 2025 Regular session: hot open, cold close On Tuesday, December 9, 2025, Johnson & Johnson shares: Volume came in at roughly 5–7 million shares, around or slightly below JNJ’s recent average daily volume of ~6.8 million shares, suggesting a normal‑liquidity, mild risk‑off session rather than a panic move. StockInvest+1 Early in the day, JNJ actually helped
10 December 2025
···
Johnson & Johnson Stock Today: Q3 Beat, Orthopaedics Spin-Off and New Cancer Data Power a 40% Rally

Johnson & Johnson Stock Today: Q3 Beat, Orthopaedics Spin-Off and New Cancer Data Power a 40% Rally

Johnson & Johnson stock (NYSE: JNJ) has quietly turned into one of 2025’s standout blue‑chip winners. As of December 9, 2025, JNJ trades around $202 per share, valuing the company at roughly $486 billion and leaving the stock up close to 40% year to date.Trefis+1 That move reflects more than just a defensive bid for a safe dividend name. Investors are reacting to a powerful combination of: Below is a detailed, news‑driven look at what’s moving Johnson & Johnson stock on December 9, 2025, and how Wall Street currently values and forecasts JNJ. Johnson & Johnson stock today: price, performance
9 December 2025
··
Eli Lilly (LLY) Stock After Hours on December 8, 2025: China Mounjaro Win, Dividend Hike and What to Watch Before Tuesday’s Open

Eli Lilly (LLY) Stock After Hours on December 8, 2025: China Mounjaro Win, Dividend Hike and What to Watch Before Tuesday’s Open

Eli Lilly and Company (NYSE: LLY) spent Monday, December 8, 2025, digesting a wave of news: a major reimbursement win for Mounjaro in China, a 15% dividend hike, new leukemia drug data, and the return of Nobel laureate Carolyn Bertozzi to its board. At the same time, intensifying competition and price cuts in the weight‑loss drug market kept pressure on the stock. By the closing bell, Lilly shares were trading just under the psychologically important $1,000 level, still near a trillion‑dollar valuation but roughly 10% below recent highs. StockAnalysis Key takeaways for LLY before the December 9, 2025 open How
9 December 2025
······
Johnson & Johnson (JNJ) Stock Outlook 2026: Talc Verdicts, Stelara Cliff and a 40% Rally – What Investors Need to Know Now

Johnson & Johnson (JNJ) Stock Outlook 2026: Talc Verdicts, Stelara Cliff and a 40% Rally – What Investors Need to Know Now

Published: December 8, 2025 – This article is for informational purposes only and is not financial advice. Key Takeaways JNJ Stock Today: Price, Performance and Dividend Johnson & Johnson (NYSE: JNJ) is trading around $202–203 per share in New York trading on December 8, 2025. Recent closing data show the stock finished at $202.48 on December 8 after a modest decline of 0.27%.StockAnalysis Over the past year, JNJ has staged a strong recovery: This rally has been strong enough that Simply Wall St describes 2025 as a “40.6% rally” year and still concludes the stock screens as undervalued on both
8 December 2025
··
Johnson & Johnson (JNJ) Stock Near Record Highs: What to Know Before the Market Opens on December 8, 2025

Johnson & Johnson (JNJ) Stock Near Record Highs: What to Know Before the Market Opens on December 8, 2025

Published: December 7, 2025 – ahead of Monday’s U.S. market open Johnson & Johnson (NYSE: JNJ) heads into Monday’s session sitting just below its 52‑week high, with fresh drug data, new access to the Chinese market and ongoing talc litigation all pulling on the share price at once. After an almost year‑long rally of roughly 40% in 2025, investors now have to decide whether JNJ is a defensive dividend giant that still has room to run — or a blue‑chip that’s priced for perfection going into 2026. Simply Wall St+1 Below is a fast pre‑market briefing based on the newest
8 December 2025
·
Johnson & Johnson (JNJ) Stock on December 6, 2025: Price, Latest News, Analyst Targets and Dividend Outlook

Johnson & Johnson (JNJ) Stock on December 6, 2025: Price, Latest News, Analyst Targets and Dividend Outlook

Johnson & Johnson (NYSE: JNJ) heads into December 2025 as one of the market’s standout large‑cap healthcare performers, combining a 2025 share‑price surge with classic “defensive” traits like steady earnings and a long dividend track record—while still carrying a very real legal overhang from talc litigation. As of the close on Friday, December 5, 2025, JNJ shares finished at $201.93, near their record territory and not far below a recent 52‑week high around $207.81. Over the past 12 months the stock has climbed roughly 35%, with some measures putting its 2025 year‑to‑date total return close to 40%, far ahead of
6 December 2025
·
Johnson & Johnson (JNJ) Stock: Price, Latest News, Analyst Forecasts and Dividend Outlook – December 5, 2025

Johnson & Johnson (JNJ) Stock: Price, Latest News, Analyst Forecasts and Dividend Outlook – December 5, 2025

Johnson & Johnson (NYSE: JNJ) stock has surged in 2025 and is now trading close to record highs, while Wall Street remains broadly positive but increasingly divided on just how much upside is left from here. As of December 5, 2025, investors are digesting a fresh analyst upgrade, a wave of institutional buying, and robust earnings – all against a backdrop of ongoing litigation and a major planned spinoff. Below is a structured look at Johnson & Johnson’s latest stock price, news, forecasts and fundamental drivers as of December 5, 2025. Key Takeaways This article is for informational purposes only
5 December 2025
·
Johnson & Johnson (JNJ) Stock on December 4, 2025: Price Action, Latest News, Analyst Targets and 2026 Outlook

Johnson & Johnson (JNJ) Stock on December 4, 2025: Price Action, Latest News, Analyst Targets and 2026 Outlook

Published: December 4, 2025 Johnson & Johnson (NYSE: JNJ) remains one of 2025’s standout defensive stocks. After a powerful run driven by stronger pharma growth, MedTech momentum and a string of acquisitions, the healthcare giant now trades close to record highs while still offering a solid dividend and relatively low volatility. At the same time, investors watching JNJ today must weigh ongoing talc litigation, looming patent expiries and a valuation that is no longer “cheap” against its upgraded sales outlook and deep pipeline. Below is a full breakdown of how JNJ stock is positioned as of December 4, 2025, including
4 December 2025
··
Johnson & Johnson (JNJ) Stock Near Record Highs: New EU Drug Approval, Oncology Deal and 2026 Outlook

Johnson & Johnson (JNJ) Stock Near Record Highs: New EU Drug Approval, Oncology Deal and 2026 Outlook

As of December 2, 2025, Johnson & Johnson (NYSE: JNJ) is trading just below all‑time highs, supported by a powerful 2025 rally, a fresh European Union drug approval, a new $3.05 billion oncology acquisition, and a planned spin‑off of its orthopaedics business. Together, these moves are reshaping the investment case for JNJ as it heads into 2026. Below is a news-style rundown of the latest price action, fundamentals, pipeline news, Wall Street forecasts and key risks that matter for Johnson & Johnson stock today. JNJ stock today: Price, market cap and performance in 2025 On performance, JNJ has easily outpaced
2 December 2025
··
Johnson & Johnson (JNJ) Stock Near Record Highs: What Investors Should Know Before the December 1, 2025 Market Open

Johnson & Johnson (JNJ) Stock Near Record Highs: What Investors Should Know Before the December 1, 2025 Market Open

Johnson & Johnson (NYSE: JNJ) heads into the new trading week sitting just under all‑time highs, after a powerful rally that’s pushed the healthcare giant toward a $500 billion market value.FinancialContent+1 With U.S. markets reopening on Monday, December 1, 2025, investors watching the premarket tape will be weighing three things: Here’s a concise, news-ready rundown of where JNJ stands before the bell. JNJ stock price snapshot heading into December 1 In short: JNJ is entering December 1 as a low‑volatility, dividend‑paying stock trading very close to record highs after an exceptional 2025 run. Fresh news and commentary (Nov. 28–30, 2025)
30 November 2025
·
Johnson & Johnson (JNJ) Stock Today, November 22, 2025: Near Record Highs Ahead of Dividend and Legal Milestones

Johnson & Johnson (JNJ) Stock Today, November 22, 2025: Near Record Highs Ahead of Dividend and Legal Milestones

Published: November 22, 2025 Johnson & Johnson stock (NYSE: JNJ) is heading into the weekend of November 22, 2025 sitting close to its 52‑week highs, buoyed by a powerful year‑to‑date rally, strong third‑quarter earnings and fresh oncology deal-making. At the same time, investors are still weighing multi‑billion‑dollar talc litigation risks and a major portfolio reshaping. Here’s what’s happening with JNJ stock right now, what’s driving the move, and the key dates and catalysts to watch. Johnson & Johnson stock today: price, range and recent move As of Friday’s close on November 21, 2025, Johnson & Johnson stock finished around $203.90
23 November 2025
Johnson & Johnson’s $3.05 Billion Halda Therapeutics Deal Signals New Oncology Push After Stelara Patent Cliff

Johnson & Johnson’s $3.05 Billion Halda Therapeutics Deal Signals New Oncology Push After Stelara Patent Cliff

Johnson & Johnson has struck a $3.05 billion cash deal to acquire Halda Therapeutics, a privately held cancer-drug developer based in New Haven, Connecticut, in one of 2025’s biggest oncology takeovers so far.Reuters+1 The move deepens J&J’s bet on cancer medicines just as sales of its long‑time blockbuster psoriasis drug Stelara are being hit hard by a wave of cheaper biosimilar rivals.Yahoo Finance+1 Key points Inside Johnson & Johnson’s Halda Therapeutics takeover J&J said on Monday that it will acquire Halda Therapeutics for $3.05 billion in cash, adding a new set of precision oncology assets to its Innovative Medicine unit.Reuters+1
17 November 2025
··
1 … 4 5 6 7

Stock Market Today

Saudi Aramco share price set for Sunday test after Tadawul ends market-making deal

Saudi Aramco share price set for Sunday test after Tadawul ends market-making deal

7 February 2026
Saudi Exchange approved Merrill Lynch KSA’s exit as market maker for Saudi Aramco, effective Feb. 8. Aramco shares closed at 25.60 riyals Thursday, down 0.06, with 22.1 million traded. The Tadawul index fell 1.3% as Brent crude dropped to $67.93. Aramco set March official selling prices at $2.10 above Argus for North America and $0.65 above ICE Brent for Western Europe.
Meta stock ends week down about 6% as Wall Street fixates on $135 billion AI capex

Meta stock ends week down about 6% as Wall Street fixates on $135 billion AI capex

7 February 2026
Meta closed down 1.3% Friday at $661.46, capping a 6.4% weekly drop as investors questioned heavy AI spending. Amazon and Alphabet also fell after outlining major capital outlays. Meta’s Instagram suffered a brief outage this week. Legal risks persist, with trials involving Meta set for next week in Los Angeles and New Mexico.
Go toTop